ONVO +43% on PR from activist shareholder, Keith Murphy—who happens to be the company founder—opposing ONVO’s reverse merger with Tarveda that was announced in Dec 2019 (#msg-152824419):
The above PR from Keith Murphy says almost nothing about ONVO, but it makes lofty claims that Murphy’s private company, Viscient Biosciences, can play a role in COVID-19 drug discovery. This was enough to cause today’s pop in ONVO’s share price, which suggests that some investors interpret Murphy’s PR as an implicit invitation for ONVO to revere-merge with Viscient instead of Tarveda.
Last Friday, ONVO acknowledged that it lacked the shareholder votes to approve the deal with Tarveda, postponing the vote until 4/7/20 (#msg-154624048).
Weird stuff is happening in biotech these days. Stay tuned.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.